Apotex Health Reports Q3 Results and Raises FY2027 Guidance
Apotex Health reported third-quarter results featuring a slight year-over-year decline in diluted earnings per share (EPS), with C$0.41 compared to C$0.43 in the prior year. When excluding contributions from the U.S. VLLP, adjusted diluted EPS stood at C$0.57 versus C$0.61 previously. Despite the dip in EPS, total revenue grew 1.1% year-over-year to C$852.9 million. Notably, organic growth excluding U.S. VLLP contributions was stronger at 4.9%. Based on these performance metrics, the company has raised its full-year 2027 guidance for both revenue growth and adjusted EBITDA margins.
Tickers: $APTX
Topics: earnings report EPS guidance upgrade revenue growth
Read the full article at Seeking Alpha
Part of the story Pembina Pipeline Reports Strong Q3 2026 Results with 99% Earnings Increase (5 articles)